Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
Scientific Reports 12(1):6666, 2022
New insights into disease progression and human translatability of the GAN DIO-NASH mouse
Join preclinical NASH experts Michael Feigh and Henrik Björk Hansen in a scientist-to-scientist talk about the latest research discoveries and advances within human translational models of non-alcoholic steatohepatitis (NASH).
Preclinical drug discovery in NASH – Narrowing the translational gap
In this webinar Principal Scientist at Gubra Henrik Björk Hansen discusses strategies to improve clinical translatability of preclinical models of NASH. The webinar introduces a diet-induced obese and biopsy-confirmed rodent model of NASH with progressive development of fibrosis and hepatocellular carcinoma, that recapitulates…
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
Clinical and Translational Science 15(5):1167-1186, 2022
Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH
International Journal of Molecular Sciences 22:6332, 2021
Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis
Liver International 41(8):1853-1866, 2021
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis
British Journal of Pharmacology 178(12):2412-2423, 2021